Objective. Cognitive behavioral therapy for chronic pain (CBT-CP) has been identified as an evidence-based adjunct or alternative to opioid pain care. However, little is known about which patients participate in CBT-CP. This study examined predictors of enrollment in a noninferiority trial of in-person vs technology-based CBT-CP for patients with chronic back pain. Setting. A single Veterans Health Affairs (VHA) medical center. Subjects. Veterans with chronic back pain. Design and Methods. For eligible participants (N ¼ 290), individual factors (demographics, distance from a VHA medical center, pain intensity, receipt of opioid prescription, and recruitment method) collected at trial screening were examined to identify predictors of enrollment (i.e., signed consent form). Of those who enrolled, duration of participation in the treatment portion of the study was examined. Results. Among eligible patients, 54% declined enrollment due to lack of interest. Regression analyses revealed that patients not in receipt of an opioid were more likely to enroll. The probability of being in the trial long enough to receive a "dose" of treatment (3 visits or more) was 0.76 (0.04). Conclusions. Overall, enrollment rates were low. However, most patients who enrolled in the study (102 of 134 signed consent) were retained and received a treatment dose. Patients not receiving opioids were more likely to enroll, suggesting that patients who are prescribed opioids, an important group for treatment outreach, are likely underengaged. Identifying predictors of enrollment in CBT-CP may help increase recruitment efficiency and assist in targeting patients who may benefit but are not currently interested in treatment.
Introduction
The US Institute of Medicine's report, Relieving Pain in America, estimates that 100 million Americans experience chronic pain [1] . The prevalence of chronic pain among veterans appears to be comparable to or higher than that of nonveterans, with significant associated effects on functioning and quality of life [2, 3] . To address this highly prevalent condition while simultaneously avoiding the harms associated with opioid treatment, recent clinical guidelines have cautioned against use of opioids as a firstline or single treatment for pain and promoted the use of nonpharmacological treatments [4, 5] . However, it appears that only a small percentage of eligible patients engage in these nonpharmacological interventions, and little is known about factors associated with the use of these interventions. For example, barriers 2018 American Academy of Pain Medicine. This work is written by US Government employees and is in the public domain in the US.
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Pain Medicine, 19, 2018, S76-S83 doi: 10.1093/pm/pny077 Original Research Article to engagement in these programs include limited physician time/knowledge to implement nonpharmacologic treatments, availability of qualified therapists/providers, challenges with adequate third party coverage of nonpharmacological treatments, and patient burden associated with traveling to and from appointments [6] .
One widely used nonpharmacological intervention for chronic pain is cognitive behavioral therapy (CBT-CP). CBT-CP focuses on reducing pain intensity and improving functioning and quality of life and is an effective alternative or addition to pharmacological treatments for chronic pain. However, participation rates are low, and there is limited evidence identifying which patients will participate. In a Veterans Health Administration (VHA) Health Services Research and Development Servicesponsored State of the Art (SOTA) meeting of research experts in pain management, low patient engagement in psychological and behavioral treatments was identified as an important barrier to wider implementation [7] . One means to examine factors associated with treatment enrollment is to examine enrollment in CBT-CP in the context of a randomized clinical trial (RCT). Currently, there are limited data available describing factors that predict which patients will enroll (i.e., "sign consent") in RCTs focused on behavioral treatments for chronic pain. Understanding the types of patients who are most likely to be interested in RCTs of CBT-CP may improve understanding of how representative CBT-CP RCT participants are of people with chronic pain more broadly, thereby more accurately contextualizing the results of these trials. This information could also be used to identify nonengaging populations and solicit their feedback in order to produce interventions that are more attractive to them or more responsive to their treatment needs.
Another factor in understanding enrollment is determining whether recruitment method is a predictor of enrollment. The pharmacologic interventions literature offers some insights regarding effective measures for enrolling participants in clinical trials. For example, one study recruiting participants with type 1 diabetes for a mechanistic, dose-finding study of an experimental medication found that self-referral (via the Internet), rather than clinic referral and staff outreach to potential participants from a diabetes registry, was more effective for enrolling participants [8] . Similarly, in a study of women with vulvodynia recruited to study the therapeutic effect of gabapentin, researchers determined that participants responding to targeted mailings (i.e., paid advertisement included in utility bills), based on potential participants' age, race, education, household income, and proximity to the research facility, were more likely to enroll than those targeted through media advertisements (newspaper/magazines/Internet), clinician referral, or community outreach efforts [9] . One perhaps more relevant study examined engaging veterans with substance use disorders in a research study. This study suggested that using a "multipronged" recruitment approach, including opt-out letters provided to patients, study advertisements, financial incentives, and study branding (e.g., a memorable study name printed on wristbands provided to interested veterans), facilitated meeting the recruitment goal well ahead of schedule and excellent participant retention [10] .
A recent noninferiority trial, the Co-Operative Pain Education and Self-management (COPES) program, compared an interactive voice response (IVR)-delivered CBT-CP intervention for veterans with chronic low back pain with traditional, individual, in-person CBT-CP treatment and demonstrated that IVR-delivered CBT-CP was not inferior to in-person in terms of reduction in pain intensity. Participants in both treatment showed statistically significant improvements in physical functioning, sleep quality, and physical quality of life, with no advantage for either treatment [11] . To better understand low rates of patient engagement in available CBT-CP services, the current study employed clinical trial enrollment as a proxy for CBT-CP participation using secondary data from the COPES trial. The primary objective of the current study was to examine demographic and painrelated variables that may predict which patients are most likely to enroll (i.e., sign a research informed consent form) in a CBT intervention for chronic pain.
Methods
Detailed descriptions of the COPES noninferiority trial research protocol and outcomes have been published elsewhere [11, 12] . The study was approved by the VA Connecticut Healthcare System (VACHS) and Yale School of Medicine institutional review boards (IRBs). Recruitment occurred from 2011 to 2015. At the time the COPES trial was conducted, VACHS offered comprehensive pain management services, including an interdisciplinary pain consultation clinic, opioid renewal clinic, CBT-CP, interventional pain clinic, physical medicine and rehabilitation services, chiropractic are, and yoga for chronic pain.
Screening and Recruitment Procedure
Potential participants were recruited using opt-out letters, clinician referral/patient advertising, and a staffed educational outreach table located in the medical center. For the opt-out letters, initial eligibility screening was conducted using administrative data from the electronic health record (EHR) to identify veterans with back painrelated diagnoses using ICD-9 codes (i.e., indicating a disorder of the back and neck) and the presence of at least moderate pain (score 4 on the 0-10 pain intensity numerical rating scale [NRS] ), reported during their most recent primary care visit. Primary care providers (PCPs) reviewed lists of their identified patients for approval (i.e., to determine whether patients had existing medical and psychiatric comorbidities that would impair their participation) to be included in the mailing. Potentially eligible patients were mailed an opt-out recruitment letter that was signed by the PCP and the principal investigator. Patients who did not opt out of further contact by notifying staff were called. Those who expressed interest underwent an initial eligibility telephone screening to confirm diagnosis of back pain, chronicity, and intensity, and absence of medical and psychiatric comorbidities identified as exclusion criteria. Eligibility questions were answered using both EHR review and patient-provided information. Participants who contacted study staff based on clinician referral or in-hospital advertisements were screened by telephone in the same manner. Finally, participants who expressed interest at the staffed educational outreach table, a table located near the entrance to the primary care clinics at the medical center that contained information about chronic pain, treatment options, and pain-focused research studies, completed a brief eligibility questionnaire, and study staff reviewed their EHR for eligibility. The telephone screening and collection of these data was covered by a waiver of written informed consent approved by the local IRB. Participants also provided verbal consent to answer eligibility questions via phone and to allow research staff to assess remaining eligibility criteria in their EHRs. For all recruitment methods, if initial screening suggested eligibility, patients were scheduled for an in-person informed consent and final eligibility confirmation visit.
Study Participants
Participants were veterans from one Northeastern VA health care system, had at least moderate back pain for more than three months, were able to walk one city block, had an absence of psychiatric and medical conditions that would impair participation (e.g., suicidality, current substance abuse, dementia, psychosis, terminal cancer, end-stage renal failure), and were without planned surgical interventions. Because the protocol required daily automated telephone reporting of painrelevant variables and treatment use, participants were required to have access to a landline or mobile telephone and be without sensory difficulties that would preclude participation (e.g., hearing difficulties that prevented telephone use). Participants in the current study broadly reflected the population of veterans with chronic pain, with women and black participants represented at least to the degree that they are present in the VA population. In the COPES noninferiority trial, patients reported a long duration of chronic pain (mean of 11 years) and had a mean of 2.9 reported pain locations [12] .
Measures
The primary outcome, treatment enrollment, was defined as signing an informed consent form. Participants who passed the initial eligibility screening and enrolled were compared with those who did not enroll in COPES. Of the 508 participants who were screened for COPES, 218 were not eligible, with the primary reasons being active substance abuse (N ¼ 74, 20%) and ineligible medical (N ¼ 44, 12%) and psychiatric (N ¼ 34, 9%) conditions. Among the 508 screened participants, 156 (42%) were eligible but declined to enroll due to lack of interest, and 134 enrolled in the trial.
Predictors of Enrollment
All predictors of enrollment were collected during the initial screening evaluation. Demographic and other variables were recorded during in-person and telephone screening of interested patients.
Demographics
Demographic variables included age, gender, race/ethnicity, and distance the participant lived from the medical center where in-person CBT-CP is delivered. Distance from the medical center was calculated in miles using Google maps using the participant's EHR-listed address and the address of the medical center. Distance was divided into three categories consistent with the parent trial's original data collection method: 0-10 miles, 11-25 miles, and greater than 25 miles from the medical center.
Pain Variables
Average pain intensity over the prior week was collected using the NRS score. The pain intensity NRS has been validated in a number of studies [13, 14] and is considered a gold standard of pain intensity assessment [15] .
Receipt of Opioid Prescription
We also examined presence of a current opioid prescription (any duration or dose) at the time of screening reported by the participant and verified via EHR. Included medications were fentanyl, codeine, morphine, methadone, hydromorphone, hydrocodone, hydrocodone/acetaminophen, oxycodone, oxycodone/acetaminophen, buprenorphine, and tramadol. This variable was recorded as present vs absent.
Recruitment Method
Recruitment method included 1) an educational outreach table, which was a staffed, pain-focused health education table containing study information, or 2) "self/provider referral," comprised of opt-out recruitment letters sent to participants, provider referrals (i.e., providers mentioned the study to patients or provided them with a study flyer, both of which required that patients contact study staff to express interest), and advertisements containing study information and a contact phone number placed in clinical care areas in the medical center. When the eligible participant declined to enroll, the reason was recorded.
Treatment Dose
To further examine participation in the CBT-CP trial, the proportion of participants who enrolled and completed an adequate "dose" of treatment (predefined as three or more treatment visits [in-person CBT-CP] or weeks [IVR-based CBT]) was analyzed. The probability of staying in the trial once enrolled was examined, as well as the proportion of participants who completed zero treatment visits and those who completed all 10 treatment visits.
Statistical Analyses
Age, gender, race/ethnicity, pain intensity at screening, receipt of an opioid prescription, distance from the VHA medical center, and recruitment method were examined as predictors of enrollment. Chi-square and t tests were used to evaluate bivariate associations with treatment enrollment; when cell size was not sufficient, we used the Fisher exact test. A multivariate logistic regression model was used to evaluate predictive factors of enrollment. Kaplan-Meier estimates were used to evaluate probability of dropout for each treatment visit number and have been presented using a survival plot with 95% confidence bands.
Results
Eligible participants (N ¼ 290) were primarily male (81%) and Caucasian (71.3%), with a mean age (SD) of 57.4 (12.5) years, and reported moderate pain intensity (mean NRS ¼ 6.7/10). With respect to opioid prescribing, 27% (75 participants of 281 eligible participants for whom we had medication data) received opioid prescriptions. The opioid morphine equivalent daily dose (MEDD) for those participants ranged from 10 mg to 990 mg. The majority of the sample (83%) received prescriptions for less than 90 mg MEDD. Of the 290 veterans who were initially eligible, 134 (46.2%) signed informed consent (i.e., enrolled) and 156 (53.8%) declined to enroll. Bivariate analyses indicated that recruitment method, receipt of an opioid prescription, and distance to the medical center significantly discriminated between enrollees and nonenrollees (P < 0.005). Age, gender, race/ethnicity, and pain intensity did not. Complete bivariate results are shown in Table 1 In order to further explore participation in the trial, a survival curve demonstrating the probability of participants' participation in each of the zero through 10 treatment visits attended was generated (Figure 1 ). The probability of being in the trial long enough to receive the predefined adequate "dose" of treatment (three weeks or more) was 0.76 (0.04). More specifically, 84 of 
Discussion
Overall enrollment rates in the trial were low, with 54% of screened eligible patients declining enrollment due to lack of interest. Thus, as suspected, many patients who could likely benefit from CBT-CP were not interested in engaging. It is not clear if patients declined participation due to concerns about research in general, such as mistrust/misunderstanding of clinical trials [16, 17] , dislike of the randomization process [16] , and concern about the time commitment [18] , or if their concerns were more specific to CBT-CP. Some suggestions for improving uptake of CBT-CP and other nonpharmacologic pain treatments were highlighted in a qualitative study by Becker and colleagues, who interviewed patients and providers with respect to barriers and facilitators of engagement in nonpharmacologic treatments [19] . Identified facilitators to engagement included providing improved marketing and treatment rationale to patients, increased access to these treatments, provider support for their use, and reinforcement of beliefs about the efficacy and standard use of nonpharmacologic treatments during patient-provider discussions of pain management approaches [19] . Results of the current study supported identified factors that have predicted enrollment in studies in the literature, including self-referral (e.g., study advertisements) and targeting patients who are most appropriate for the treatment (e.g., via opt-out letters) [8] [9] [10] . In the current study, those who were self/provider-referred (i.e., contacted study staff) were more likely to enroll than those recruited via the staffed education outreach table.
Conversely, there were patients who expressed interest in enrolling but were not eligible. A meaningful number of those patients were excluded due to active substance abuse and psychiatric comorbidities, such as significant depression [20, 21] . These patients have traditionally been excluded from trials due to concerns that they may not be able to meaningfully engage in and benefit from CBT-CP or may not have outcomes that are as favorable. However, these comorbidities are common among patients with chronic pain and those who receive care in VHA facilities. Thus, efficacy and effectiveness data for CBT-CP are often not available for this important population of patients, and data are needed to determine if their exclusion from these trials is warranted. The US Department of Health and Human Services, the Department of Defense, and the Department of Veterans Affairs have recently partnered to announce the funding of 11 pragmatic trials of nonpharmacological interventions for chronic pain that will examine the real-world effectiveness of treatments, in part by loosening eligibility criteria and examining if treatments are effective in groups that are routinely excluded from most efficacy/effectiveness trials [22] . Results of the current study showed that receipt of an opioid prescription and recruitment method affected the likelihood of enrolling in a clinical trial of CBT-CP. Other factors like age, gender, race/ethnicity, and pain intensity were not significantly related to enrollment. Perhaps counterintuitively, pain intensity was not predictive of enrollment, indicating that among people with at least moderate intensity, those with higher levels of pain were not more likely to enroll in this study. Participants not prescribed opioids were more likely to enroll than those who were prescribed opioids at the time of screening. Perhaps these participants have a specific preference for nonpharmacologic treatments in light of concerns about the potential harms (unpleasant side effects, addiction, and overdose risk) and stigma associated with chronic opioid therapy for pain. Providers may also be more likely to suggest CBT-CP interventions for patients who are not prescribed opioid medications as a nonpharmacologic option with evidence of efficacy and/or in an effort to offer a treatment option for those patients who have struggled with opioid tolerance/misuse and are no longer prescribed opioids. This finding, though very preliminary, echoes the finding of a meta-analysis of HIV prevention programs [23] in that patients already exhibiting an affinity for the underlying treatment (i.e., high condom use for HIV prevention programs and no opioid use at baseline for CBT-CP) were more likely to engage in behavioral interventions. Ultimately, further research will be necessary to replicate this finding and examine more specifically why patients who use opioids are more likely to decline to engage in CBT-CP or nonpharmacologic interventions. Answers to these questions can guide recruitment efforts for trials and engagement efforts in clinical settings, targeting patients who are not prescribed opioids as particularly likely to enroll and examining barriers to enrollment among those who are prescribed opioids.
The educational outreach table recruitment was associated with lower rates of enrollment. The table, which included a face-to-face encounter with staff, may have fared more poorly because it did not require any patient initiative and could have promoted a social desirability bias, with more people initially agreeing to participate who were not truly interested in engaging. Although the educational outreach table yielded the most enrollees overall, it was less efficient than other methods and is inherently more time-consuming in that it required more staff and scheduled hours devoted to the recruitment process. One aspect of recruiting using the staffed table is the ability to provide patients with information about chronic pain, but prior examinations of the use of educational materials to enhance recruitment has yielded mixed outcomes. One systematic review of recruitment methods found that providing education about the particular condition being studied significantly improved enrollment [24] . However, a Cochrane review determined that providing adjunctive materials to potential participants did not boost recruitment rates [25] .
There is limited evidence describing factors that predict participation in nonpharmacologic treatments for chronic pain. Such interventions (e.g., CBT-CP) have been identified by regulatory agencies and policy groups as suggestions for firstline treatments [5, 26] . Given the broader systemic issues associated with CBT-CP and similar treatments for pain, such as poor insurance reimbursement, limited availability of trained specialists, tendency for these treatments to be used as "last resort" options or minimally promoted in health care settings, and tendency for these treatments to be offered primarily to patients with mental health comorbidities, it is important to improve efforts to engage patients in these treatments when they are offered and available. Future research examining predictors of engagement in CBT-CP is essential. To that end, an ongoing implementation trial of the COPES IVR-based intervention (ClinicalTrials.gov Identifier: NCT02724930) may offer insight into the effectiveness of specific techniques to improve uptake and identification of barriers and facilitators of CBT-CP engagement in the clinical setting.
Despite challenges with enrolling eligible patients with chronic back pain, similar to those also noted in other clinical trials (e.g., [16, 18] ), one especially promising element highlighted in the current study was the tendency for enrolled participants to remain in the trial and complete the CBT-CP treatment. While few studies have examined engagement in psychological treatments for chronic pain and there were no studies identified that examined likelihood of enrolling in a clinical trial of CBT-CP, two studies have noted similar completion rates for CBT-CP. A randomized controlled trial comparing a tailored CBT condition that included motivational interviewing strategies with a standard CBT-CP control [27] determined that engagement, defined as attending at least three treatment sessions, across the sample was high and did not differ between treatment groups. Data examined for dissemination of CBT-CP delivered by a national sample of VHA psychologists revealed that 79% of 148 patients engaged in the dissemination program completed a full course of treatment (11 sessions) [28] .
These findings may argue for placing more emphasis on refining recruitment strategies and developing a better understanding of how to make psychological treatments and clinical trials more attractive and better meet patients' needs.
This study has several limitations that should be noted. The current study is limited in scope by the small number of variables collected during the screening process, which limited the analyses to examining participation in this trial. It is also not clear how generalizable these results are. VHA patients may be less likely to enroll in trials of CBT-CP because it is already available clinically (e.g., at the study site), and many VHA patients can obtain it without a copay. VHA patients likely have greater access to specialty care services, either in the VHA or through VHA payment for outside services (i.e., Community Care), than non-VHA patients. Other factors that could confound or moderate these results may include past participation in research, past or current treatments for chronic pain, past personal or otherwise experienced opioid addiction, social support, and/or additional disease burden (such as mental health). In addition, the current study used enrollment in a clinical trial as a proxy for engaging participants in a nonpharmacological treatment; these results may not apply in a clinical setting. Future conduct of implementation studies where techniques designed to increase treatment uptake are evaluated and systematic evaluations of barriers and facilitators to uptake are conducted may be well suited to examining uptake of CBT-CP.
The current study highlights some factors that may affect enrollment in clinical trials of CBT-CP and may also pertain to engaging patients in CBT-CP delivered in clinical settings. Our enrollment and participation findings, as well as those highlighted in the literature [19, 21] , are perhaps an indicator that targeting veterans who express interest in and/or who are already engaging in nonpharmacologic interventions and who are not (or are no longer) receiving opioid medications to offer them CBT-CP may improve their outcomes, as they may be likely to "stick with" this treatment once enrolled.
